A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

NCT03856996 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Stable CH505TF gp120
BIOLOGICAL: Transient CH505TF gp120
BIOLOGICAL: Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)